Export 67 results:
Author Title [ Type(Desc)] Year
Filters: Author is Van Veldhuisen, P  [Clear All Filters]
Journal Article
J. Hibbard, Wilkins, I., Sun, L., Gregory, K., Haberman, S., Hoffman, M., Kominiarek, M., Reddy, U., Bailit, J., Branch, D., Burkman, R., Gonzalez-Quintero, V., Hatjis, C., Landy, H., Ramirez, M., Van Veldhuisen, P., Troendle, J., Zhang, J., and Labor, Con Safe, Respiratory Morbidity in Late Preterm Births, JAMA, vol. 304, pp. 419-425, 2010.
C. Chan, Ip, M., Van Veldhuisen, P., Oden, N., Scott, I., Tolentino, M., and Blodi, B., SCORE Study Report #11: Incidences of Neovascular Events in Eyes with Retinal Vein Occlusion, Ophthalmology, vol. 118, pp. 1364-1372, 2011.
D. Weinberg, Wahle, A., Ip, M., Scott, I., Van Veldhuisen, P., Blodi, B., and Group, S. C. O. R. E. Study Inve, SCORE Study Report 12: Development of Venous Collaterals in the SCORE Study, Retina, vol. 33, pp. 287-295, 2013.
I. U. Scott, Blodi, B., Ip, M., Van Veldhuisen, P., Oden, N., Chan, C., Gonzalez, V., and Group, S. C. O. R. E. Study Inve, SCORE Study Report 2: Interobserver Agreement Between Investigator and Reading Center Classification of Retinal Vein Occlusion Type, Ophthalmology, vol. 116, pp. 756-761, 2009.
M. Ip, Oden, N., Scott, I., Van Veldhuisen, P., Blodi, B., Figueroa, M., Antoszyk, A., Elman, M., and Group, S. C. O. R. E. Study Inve, SCORE Study Report 3: Study Design and Baseline Characteristics, Ophthalmology, vol. 116, pp. 1770-1777 e1, 2009.
N. Oden, Van Veldhuisen, P., Scott, I., Ip, M., and Group, S. C. O. R. E. Study Inve, SCORE Study Report 8: Closed Tests for All Pairwise Comparisons of Means, Drug Inf J, vol. 44, pp. 405-420, 2010.
W. Fitzsimmons, Thompson, D., Hariharan, S., and Van Veldhuisen, P., Serum Creatinine as a Surrogate Endpoint for Graft Loss in Kidney Transplantation Validation Efforts from Multicenter Trials, 2002.
M. D. Sorrentino, Charsha-May, D. E., Angert, A., Meissner, C., Pauly, T., L Pena, P., Prober, C., Rodriguez, W., Rodriguez-Santa, J., Sanchez, P., Simoes, E., and Van Veldhuisen, P., Severity of RSV LRI hospitalizations in 33 to 35 week and 36 week gestational age infants, 2001.
A. Domalpally, Blodi, B., Scott, I., Ip, M., Oden, N., Lauer, A., Van Veldhuisen, P., and Group, T. S. C. O. R. E. Stud, The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Optical Coherence Tomograms: SCORE Study Report 4, Arch Ophthalmol, vol. 127, pp. 1461-1467, 2009.
B. Blodi, Domalpally, A., Scott, I., Ip, M., Oden, N., Elledge, J., Warren, K., Altaweel, M., Kim, J., Van Veldhuisen, P., and Group, S. C. O. R. E. Study Rese, Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Stereoscopic Color Fundus Photographs and Fluorescein Angiograms: SCORE Study Report 9, Archives of Ophthalmology, vol. 128, pp. 1140-1145, 2010.
I. Hand, Boron, M., and Van Veldhuisen, P., Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry, 2001.
A. Krupnick, Serle, J., Van Veldhuisen, P., Lind, L., Clarke, J., Singer, G., and Lebwohl, M., Tacrolimus ointment for the treatment of eyelid dermatitis, Cutis, vol. 73, pp. 267-71, 2004.
A. K. Freeman, Linowski, G. C., Brady, C., Lind, L., Van Veldhuisen, P., Singer, G., and Lebwohl, M., Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas, J Amer Acad Dermatology, vol. 48, pp. 564-8, 2003.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial, Proceedings of the National Academy of Science USA, vol. 96, pp. 7462-66, 1999.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial., Proc Natl Acad Sci U S A, vol. 96, no. 13, pp. 7462-6, 1999.
T. A. Gonwa, Johnson, C., Ahsan, N., ,, Stegall, M., Hardy, M., Metzger, R., Shield, C., Rocher, L., Scandling, J., Sorensen, J., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Salm, K., Tolzman, D., Scotellaro, P., and Fitzsimmons, W., Untitled, 2000.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Risso, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., The use of monoclonal therapy in the treatment of intraocular inflammatory disease, 2000.